The Latest Breaking News from Obesity

The council rejects the principle that a certain weight equals healthiness

Ipsos survey asked people in 31 countries what they thought of their health and healthcare

Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.

Scientists say that testing for fatty acids could make it easier to identify children at risk of various conditions.

With rising rates of obesity in the U.S. and increasing attention being paid to the health harms of processed foods, it’s clear that far more could be done to help consumers make healthy food choices.

From doctors’ offices to family gatherings, larger-bodied people report being bombarded with unsolicited advice about their eating and exercise habits. The underlying message? They “just need to lose weight” to fix almost any health problem.

Having more than the normal range of body mass index (BMI) in childhood could elevate the risk of developing schizophrenia in adulthood, the study revealed.

The agency plans to make a formal proposal in October

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

Novo Nordisk (NVO) continues strengthening its obesity portfolio and marking new milestones. The company’s solid product demand, strategic investments, and developments are the key drivers for its growth and success. So, let’s examine whether NVO is an ideal investment choice. Read more to find out.

Similar adverts for foods and drinks high in fat, salt and sugar are already not allowed to be displayed on the Underground, Overground, buses or bus shelters